GLP-1 Pricing Index · FormBlends network
See what a GLP-1 really costs each month, with every price dated.
Brand list prices, manufacturer self-pay tiers, savings cards, Medicare and Medicaid status, and compounded ranges, in one dated index with a true-monthly-cost calculator.
- $299 / $399 / $449
- LillyDirect self-pay tiers for tirzepatide vials
- Lilly's own self-pay vial prices for tirzepatide, by dose.
- $50 / month
- Medicare Bridge price, July 1, 2026 to December 31, 2027
- What Medicare will charge for covered GLP-1s under the Bridge program from July 2026.
- 13 states
- cover GLP-1s for obesity under fee-for-service Medicaid
- The Medicaid programs that cover GLP-1s for obesity today. Most still do not.
Start here
Three ways in, depending on what you need right now
- 01True monthly cost calculatorInsurance, savings card, self-pay, Medicare Bridge or a compounded offer: monthly, per dose and per mg.
- 02Medicare and GLP-1s in 2026: the Part D exclusion, the $50 Bridge, and the 2027 pricesBy law, Medicare Part D cannot pay for a drug prescribed for weight loss. It does pay for GLP-1s for diabetes.
- 03Browse prices9 pages, most recently updated September 4, 2026
Interactive
The calculator
Each runs in your browser, shows its formula, and prints a dated assumptions note. Nothing you type leaves the page.
Reading
Start with these
Each page opens with a plain-English summary, a figure drawn from the data, the numbers that matter, and what it means if you're considering treatment.
Coverage
Medicare and GLP-1s in 2026: the Part D exclusion, the $50 Bridge, and the 2027 prices
You'll get: By law, Medicare Part D cannot pay for a drug prescribed for weight loss. It does pay for GLP-1s for diabetes.
Why Medicare Part D cannot cover GLP-1s for weight loss, what it does cover, how the $50 Medicare GLP-1 Bridge works through 2027, and the 2027 prices.
Methodology
Methodology: how the compounded GLP-1 prices were collected, and what all-in means
You'll get: Every compounded price here is what a provider published on a given date, turned into an all-in cost per 28 days.
The rules behind the compounded price table: the 28-day all-in unit, the two reference doses, prepaid terms, observation methods, and FormBlends' rows.
Methodology
Price per milligram explained: the arithmetic, worked on real 2026 prices, and when it misleads
You'll get: Price per milligram is the price of a fill divided by the total milligrams in it.
How to turn a fill price into a per-dose and per-milligram figure, why the same drug costs far less per mg at higher strengths, and when per-mg misleads.
Methodology
Why a compounded vial and a brand pen are not prices for the same product
You'll get: A brand pen is an FDA-approved drug with a label, a fixed dose and a published list price.
Why compounded semaglutide or tirzepatide and the brand pens are not two prices for one product: what approval covers and how to compare honestly.
Prices
GLP-1 list prices at a glance, with dates
You'll get: A list price is what the manufacturer publishes before any discount, insurance or program. Every other price is measured from it.
One table of the U.S. list price for Zepbound, Mounjaro, Wegovy, Ozempic, the Ozempic pill, Saxenda and Foundayo, what the list price is per, where it was read and when, and what changes on January 1, 2027.
Live updates
What changed since this site was written
Sources checked October 23, 2026, refreshed every six hours.
Newest on PubMed
Papers indexed in the last year matching cost and spending on GLP-1 drugs (43 in total).
- Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis
Diabetes Obes Metab · November 1, 2026 · PubMed 42638166
- Economic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran
J Diabetes Metab Disord · October 17, 2026 · PubMed 42894545
- Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity
Diabetes Obes Metab · October 14, 2026 · PubMed 42875827
- The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment
Obesity (Silver Spring) · October 7, 2026 · PubMed 42844829
- Manufacturer Coupon Use and Patient and Payer Spending During GLP-1 Treatment Episodes
J Gen Intern Med · October 6, 2026 · PubMed 42839208
FDA and enforcement tracker
FormBlends research feed, data as of September 4, 2026.
September 1, 2026 · Adverse-event report update
FDA GLP-1 concerns page updated: 990 adverse-event reports for compounded semaglutide and >730 for compounded tirzepatide (as of May 31, 2026); border screening and fake-pharmacy labelsAugust 28, 2026 · Label or price event
FDA approves Mounjaro (tirzepatide) to reduce MACE risk in adults with type 2 diabetes (SURPASS-CVOT)August 27, 2026 · Court decision
Fifth Circuit affirms summary judgment for FDA in both GLP-1 shortage cases (Nos. 25-10600 tirzepatide; 25-10758 semaglutide)August 24, 2026 · FDA warning letter
FDA warning letters to five peptide vendors: Peak Performance Peptides (735127), Royal Peptides (734884), NuScience Peptides (733652), Peptide Partners (735063), TXP Innovations dba Tex Peptides (735067)August 24, 2026 · FDA warning letter
FDA warning letter: TXP Innovations LLC dba Tex Peptides (Unapproved New Drugs/Misbranded)
Compounded price index
Median all-in cash price per 28 days across providers, as of September 3, 2026.
- semaglutide, month 1 at 0.25 mg/week
- $197
- median of 14 providers
- semaglutide, month 4 at 1 mg/week
- $199
- median of 13 providers
- tirzepatide, month 1 at 2.5 mg/week
- $268
- median of 14 providers
- tirzepatide, month 4 at 5 mg/week
- $299
- median of 12 providers
- September 3, 2026: Index, All, baseline 51 rows. First weekly snapshot. Changes against this baseline will be listed here with the date they were observed.
PubMed lists come from NCBI E-utilities and are not reviewed by us before they appear. Feeds are FormBlends Research data (CC BY 4.0); FormBlends sells compounded GLP-1 drugs and appears in the price index under the same rules as every other provider. Compounded drugs are not FDA approved.
Browse
Sections
19 pages across 4 sections, each sourced to a label, a trial or a dated manufacturer page.
Prices
You'll get: 9 sourced pages, each with a plain-English opener
One table of the U.S. list price for Zepbound, Mounjaro, Wegovy, Ozempic, the Ozempic pill, Saxenda and...
Programs
You'll get: 4 sourced pages, each with a plain-English opener
How Lilly's self-pay program works as of September 2026: the $299 to $449 Zepbound tiers, the prices outside...
Coverage
You'll get: 3 sourced pages, each with a plain-English opener
Why Medicare Part D cannot cover GLP-1s for weight loss, what it does cover, how the $50 Medicare GLP-1...
Methodology
You'll get: 3 sourced pages, each with a plain-English opener
The rules behind the compounded price table: the 28-day all-in unit, the two reference doses, prepaid terms,...
How to read a GLP-1 price
Almost nobody pays the list price, and almost every quoted monthly price is really a 28-day price, which is 13 fills a year rather than 12. Savings cards have a floor, a per-fill cap and often an annual cap, so the $25 headline lasts only while the plan pays the rest. Self-pay tiers step up with the dose. Compounded offers bundle fees, memberships and shipping in different ways. Every page here separates those pieces and dates them.
What this index does not do
It does not rank providers, recommend a product, or treat compounded and brand prices as prices for the same thing. Compounded semaglutide and tirzepatide are not FDA approved and are not interchangeable with Zepbound, Mounjaro, Wegovy or Ozempic. Prices change without notice; the access date on each figure tells you how fresh it is, and the methodology page tells you how it was collected.